QuidelOrtho Co. (NASDAQ:QDEL) Position Boosted by International Assets Investment Management LLC

International Assets Investment Management LLC raised its holdings in shares of QuidelOrtho Co. (NASDAQ:QDEL) by 4,460.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,560 shares of the company’s stock after acquiring an additional 4,460 shares during the quarter. International Assets Investment Management LLC’s holdings in QuidelOrtho were worth $208,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Greenleaf Trust bought a new stake in shares of QuidelOrtho in the 3rd quarter valued at approximately $268,000. Everence Capital Management Inc. bought a new stake in shares of QuidelOrtho in the 3rd quarter valued at approximately $388,000. Allspring Global Investments Holdings LLC grew its stake in shares of QuidelOrtho by 970.0% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 7,661 shares of the company’s stock valued at $349,000 after buying an additional 6,945 shares in the last quarter. First Citizens Bank & Trust Co. acquired a new stake in QuidelOrtho in the 3rd quarter worth approximately $307,000. Finally, Hunter Perkins Capital Management LLC lifted its holdings in shares of QuidelOrtho by 2.9% during the third quarter. Hunter Perkins Capital Management LLC now owns 18,588 shares of the company’s stock worth $848,000 after buying an additional 530 shares during the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

QuidelOrtho Trading Up 1.1 %

NASDAQ QDEL opened at $39.96 on Thursday. The business’s 50-day moving average price is $42.34 and its two-hundred day moving average price is $40.43. QuidelOrtho Co. has a 12 month low of $29.74 and a 12 month high of $75.86. The firm has a market capitalization of $2.69 billion, a PE ratio of -1.44 and a beta of 0.12. The company has a current ratio of 1.44, a quick ratio of 0.79 and a debt-to-equity ratio of 0.70.

Analyst Upgrades and Downgrades

QDEL has been the subject of a number of recent research reports. UBS Group started coverage on QuidelOrtho in a research note on Thursday, September 19th. They issued a “neutral” rating and a $50.00 target price for the company. Craig Hallum upgraded QuidelOrtho from a “hold” rating to a “buy” rating and raised their price target for the company from $40.00 to $57.00 in a report on Thursday, September 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 target price on shares of QuidelOrtho in a research note on Friday, August 16th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, QuidelOrtho presently has a consensus rating of “Hold” and an average price target of $58.83.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.